<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37060359</PMID><DateCompleted><Year>2023</Year><Month>05</Month><Day>22</Day></DateCompleted><DateRevised><Year>2023</Year><Month>05</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1420-908X</ISSN><JournalIssue CitedMedium="Internet"><Volume>72</Volume><Issue>5</Issue><PubDate><Year>2023</Year><Month>May</Month></PubDate></JournalIssue><Title>Inflammation research : official journal of the European Histamine Research Society ... [et al.]</Title><ISOAbbreviation>Inflamm Res</ISOAbbreviation></Journal><ArticleTitle>CX<sub>3</sub>CR1 modulates SLE-associated glomerulonephritis and cardiovascular disease in MRL/lpr mice.</ArticleTitle><Pagination><StartPage>1083</StartPage><EndPage>1097</EndPage><MedlinePgn>1083-1097</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00011-023-01731-1</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Patients with systemic lupus erythematosus (SLE) often develop multi-organ damages including heart and kidney complications. We sought to better define the underlying mechanisms with a focus on the chemokine receptor CX<sub>3</sub>CR1.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We generated Cx3cr1-deficient MRL/lpr lupus-prone mice through backcrossing. We then employed heterozygous intercross to generate MRL/lpr littermates that were either sufficient or deficient of CX<sub>3</sub>CR1. The mice were also treated with either Lactobacillus spp. or a high-fat diet (HFD) followed by assessments of the kidney and heart, respectively.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Cx3cr1<sup>-/-</sup> MRL/lpr mice exhibited a distinct phenotype of exacerbated glomerulonephritis compared to Cx3cr1<sup>+/+</sup> littermates, which was associated with a decrease of spleen tolerogenic marginal zone macrophages and an increase of double-negative T cells. Interestingly, upon correction of the gut microbiota with Lactobacillus administration, the phenotype of exacerbated glomerulonephritis was reversed, suggesting that CX<sub>3</sub>CR1 controls glomerulonephritis in MRL/lpr mice through a gut microbiota-dependent mechanism. Upon treatment with HFD, Cx3cr1<sup>-/-</sup> MRL/lpr mice developed significantly more atherosclerotic plaques that were promoted by Ly6C<sup>+</sup> monocytes. Activated monocytes expressed ICOS-L that interacted with ICOS-expressing follicular T-helper cells, which in turn facilitated a germinal center reaction to produce more autoantibodies. Through a positive feedback mechanism, the increased circulatory autoantibodies further promoted the activation of Ly6C<sup>+</sup> monocytes and their display of ICOS-L.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">We uncovered novel, Cx3cr1 deficiency-mediated pathogenic mechanisms contributing to SLE-associated glomerulonephritis and cardiovascular disease.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s), under exclusive licence to Springer Nature Switzerland AG.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Cabana-Puig</LastName><ForeName>Xavier</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Biomedical Sciences and Pathobiology, Virginia Tech, Blacksburg, VA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Lu</LastName><ForeName>Ran</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Biomedical Sciences and Pathobiology, Virginia Tech, Blacksburg, VA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biological Sciences, Virginia Tech, Blacksburg, VA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Geng</LastName><ForeName>Shuo</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Biological Sciences, Virginia Tech, Blacksburg, VA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Michaelis</LastName><ForeName>Jacquelyn S</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Center for Bioinformatics and Computational Biology, University of Maryland, College Park, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oakes</LastName><ForeName>Vanessa</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Biomedical Sciences and Pathobiology, Virginia Tech, Blacksburg, VA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Armstrong</LastName><ForeName>Caitlin</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Biomedical Sciences and Pathobiology, Virginia Tech, Blacksburg, VA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biological Sciences, Virginia Tech, Blacksburg, VA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Testerman</LastName><ForeName>James C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Department of Biomedical Sciences and Pathobiology, Virginia Tech, Blacksburg, VA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liao</LastName><ForeName>Xiaofeng</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Biomedical Sciences and Pathobiology, Virginia Tech, Blacksburg, VA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alajoleen</LastName><ForeName>Razan</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Biomedical Sciences and Pathobiology, Virginia Tech, Blacksburg, VA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Appiah</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Biomedical Sciences and Pathobiology, Virginia Tech, Blacksburg, VA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Yao</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Biological Sciences, Virginia Tech, Blacksburg, VA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reilly</LastName><ForeName>Christopher M</ForeName><Initials>CM</Initials><AffiliationInfo><Affiliation>Edward Via College of Osteopathic Medicine, Blacksburg, VA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Liwu</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Biological Sciences, Virginia Tech, Blacksburg, VA, USA. lwli@vt.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Luo</LastName><ForeName>Xin M</ForeName><Initials>XM</Initials><AffiliationInfo><Affiliation>Department of Biomedical Sciences and Pathobiology, Virginia Tech, Blacksburg, VA, USA. xinluo@vt.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>HL163948</GrantID><Acronym>NH</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AR067418</GrantID><Acronym>NH</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HL163948</GrantID><Acronym>NH</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AR067418</GrantID><Acronym>NH</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>04</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Inflamm Res</MedlineTA><NlmUniqueID>9508160</NlmUniqueID><ISSNLinking>1023-3830</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000073883">CX3C Chemokine Receptor 1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001323">Autoantibodies</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000073883" MajorTopicYN="N">CX3C Chemokine Receptor 1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019463" MajorTopicYN="N">Mice, Inbred MRL lpr</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002318" MajorTopicYN="Y">Cardiovascular Diseases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005921" MajorTopicYN="Y">Glomerulonephritis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001323" MajorTopicYN="N">Autoantibodies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Atherosclerosis</Keyword><Keyword MajorTopicYN="N">CX3CR1</Keyword><Keyword MajorTopicYN="N">Glomerulonephritis</Keyword><Keyword MajorTopicYN="N">Gut microbiota</Keyword><Keyword MajorTopicYN="N">High-fat diet</Keyword><Keyword MajorTopicYN="N">SLE</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>1</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>4</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>3</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>5</Month><Day>22</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>4</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>4</Month><Day>15</Day><Hour>11</Hour><Minute>2</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37060359</ArticleId><ArticleId IdType="doi">10.1007/s00011-023-01731-1</ArticleId><ArticleId IdType="pii">10.1007/s00011-023-01731-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Tsokos GC. Systemic lupus erythematosus. N Engl J Med. 2011;365:2110&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">22129255</ArticleId></ArticleIdList></Reference><Reference><Citation>Lech M, Anders HJ. The pathogenesis of lupus nephritis. J Am Soc Nephrol. 2013;24:1357&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pubmed">23929771</ArticleId><ArticleId IdType="pmc">3752952</ArticleId></ArticleIdList></Reference><Reference><Citation>Restivo V, Candiloro S, Daidone M, Norrito R, Cataldi M, Minutolo G, et al. Systematic review and meta-analysis of cardiovascular risk in rheumatological disease: Symptomatic and non-symptomatic events in rheumatoid arthritis and systemic lupus erythematosus. Autoimmun Rev. 2021;21(1): 102925.</Citation><ArticleIdList><ArticleId IdType="pubmed">34454117</ArticleId></ArticleIdList></Reference><Reference><Citation>Skaggs BJ, Grossman J, Sahakian L, Perry L, FitzGerald J, Charles-Schoeman C, et al. A panel of biomarkers associates with increased risk for cardiovascular events in women with systemic lupus erythematosus. ACR Open Rheumatol. 2021;3:209&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">33605563</ArticleId><ArticleId IdType="pmc">8063147</ArticleId></ArticleIdList></Reference><Reference><Citation>Tektonidou MG, Wang Z, Dasgupta A, Ward MM. Burden of serious infections in adults with systemic lupus erythematosus: a national population-based study, 1996&#x2013;2011. Arthritis Care Res (Hoboken). 2015;67:1078&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pubmed">25732901</ArticleId></ArticleIdList></Reference><Reference><Citation>Imai T, Hieshima K, Haskell C, Baba M, Nagira M, Nishimura M, et al. Identification and molecular characterization of fractalkine receptor CX3CR1, which mediates both leukocyte migration and adhesion. Cell. 1997;91:521&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">9390561</ArticleId></ArticleIdList></Reference><Reference><Citation>Bazan JF, Bacon KB, Hardiman G, Wang W, Soo K, Rossi D, et al. A new class of membrane-bound chemokine with a CX3C motif. Nature. 1997;385:640&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">9024663</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan Y, Lloyd C, Zhou H, Dolich S, Deeds J, Gonzalo JA, et al. Neurotactin, a membrane-anchored chemokine upregulated in brain inflammation. Nature. 1997;387:611&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">9177350</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia GE, Xia Y, Chen S, Wang Y, Ye RD, Harrison JK, et al. NF-kappaB-dependent fractalkine induction in rat aortic endothelial cells stimulated by IL-1&#x3b2;, TNF-&#x3b1;, and LPS. J Leukoc Biol. 2000;67:577&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">10770292</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirose S, Lin Q, Ohtsuji M, Nishimura H, Verbeek JS. Monocyte subsets involved in the development of systemic lupus erythematosus and rheumatoid arthritis. Int Immunol. 2019;31:687&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pubmed">31063541</ArticleId><ArticleId IdType="pmc">6794944</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiu F, Li Y, Zhu Y, Li G, Lei F, Zhang S, et al. CX3CR1 might be a promising predictor of systemic lupus erythematosus patients with pulmonary fibrosis. Scand J Immunol. 2021;94: e13038.</Citation><ArticleIdList><ArticleId IdType="pubmed">33665864</ArticleId></ArticleIdList></Reference><Reference><Citation>Yajima N, Kasama T, Isozaki T, Odai T, Matsunawa M, Negishi M, et al. Elevated levels of soluble fractalkine in active systemic lupus erythematosus: potential involvement in neuropsychiatric manifestations. Arthritis Rheum. 2005;52:1670&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">15934075</ArticleId></ArticleIdList></Reference><Reference><Citation>Segerer S, Hughes E, Hudkins KL, Mack M, Goodpaster T, Alpers CE. Expression of the fractalkine receptor (CX3CR1) in human kidney diseases. Kidney Int. 2002;62:488&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pubmed">12110009</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakatani K, Yoshimoto S, Iwano M, Asai O, Samejima K, Sakan H, et al. Fractalkine expression and CD16+ monocyte accumulation in glomerular lesions: association with their severity and diversity in lupus models. Am J Physiol Renal Physiol. 2010;299:F207&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pubmed">20410215</ArticleId></ArticleIdList></Reference><Reference><Citation>Inoue A, Hasegawa H, Kohno M, Ito MR, Terada M, Imai T, et al. Antagonist of fractalkine (CX3CL1) delays the initiation and ameliorates the progression of lupus nephritis in MRL/lpr mice. Arthritis Rheum. 2005;52:1522&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">15880599</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng L, Chen S, Garcia GE, Xia Y, Siani MA, Botti P, et al. Prevention of crescentic glomerulonephritis by immunoneutralization of the fractalkine receptor CX3CR1 rapid communication. Kidney Int. 1999;56:612&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">10432400</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao X, Ren J, Reihl A, Pirapakaran T, Sreekumar B, Cecere TE, et al. Renal-infiltrating CD11c+ cells are pathogenic in murine lupus nephritis through promoting CD4+ T cell responses. Clin Exp Immunol. 2017. https://doi.org/10.1111/cei.13017 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cei.13017</ArticleId><ArticleId IdType="pubmed">28876451</ArticleId><ArticleId IdType="pmc">5721231</ArticleId></ArticleIdList></Reference><Reference><Citation>Hochheiser K, Heuser C, Krause TA, Teteris S, Ilias A, Weisheit C, et al. Exclusive CX3CR1 dependence of kidney DCs impacts glomerulonephritis progression. J Clin Invest. 2013;123:4242&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pubmed">23999431</ArticleId><ArticleId IdType="pmc">3784547</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu F, Dai S, Feng D, Qin Z, Peng X, Sakamuri S, et al. Distinct fate, dynamics and niches of renal macrophages of bone marrow or embryonic origins. Nat Commun. 2020;11:2280.</Citation><ArticleIdList><ArticleId IdType="pubmed">32385245</ArticleId><ArticleId IdType="pmc">7210253</ArticleId></ArticleIdList></Reference><Reference><Citation>Cormican S, Griffin MD. Fractalkine (CX3CL1) and its receptor CX3CR1: a promising therapeutic target in chronic kidney disease? Front Immunol. 2021;12: 664202.</Citation><ArticleIdList><ArticleId IdType="pubmed">34163473</ArticleId><ArticleId IdType="pmc">8215706</ArticleId></ArticleIdList></Reference><Reference><Citation>Grone HJ, Cohen CD, Grone E, Schmidt C, Kretzler M, Schlondorff D, et al. Spatial and temporally restricted expression of chemokines and chemokine receptors in the developing human kidney. J Am Soc Nephrol. 2002;13:957&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pubmed">11912255</ArticleId></ArticleIdList></Reference><Reference><Citation>Landsman L, Bar-On L, Zernecke A, Kim KW, Krauthgamer R, Shagdarsuren E, et al. CX3CR1 is required for monocyte homeostasis and atherogenesis by promoting cell survival. Blood. 2009;113:963&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">18971423</ArticleId></ArticleIdList></Reference><Reference><Citation>McDermott DH, Fong AM, Yang Q, Sechler JM, Cupples LA, Merrell MN, et al. Chemokine receptor mutant CX3CR1-M280 has impaired adhesive function and correlates with protection from cardiovascular disease in humans. J Clin Invest. 2003;111:1241&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">12697743</ArticleId><ArticleId IdType="pmc">152935</ArticleId></ArticleIdList></Reference><Reference><Citation>Mionnet C, Buatois V, Kanda A, Milcent V, Fleury S, Lair D, et al. CX3CR1 is required for airway inflammation by promoting T helper cell survival and maintenance in inflamed lung. Nat Med. 2010;16:1305&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">21037587</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonacina F, Martini E, Svecla M, Nour J, Cremonesi M, Beretta G, et al. Adoptive transfer of CX3CR1 transduced-T regulatory cells improves homing to the atherosclerotic plaques and dampens atherosclerosis progression. Cardiovasc Res. 2021;117:2069&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pubmed">32931583</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong L, Nordlohne J, Ge S, Hertel B, Melk A, Rong S, et al. T cell CX3CR1 mediates excess atherosclerotic inflammation in renal impairment. J Am Soc Nephrol. 2016;27:1753&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">26449606</ArticleId></ArticleIdList></Reference><Reference><Citation>Dagkalis A, Wallace C, Hing B, Liversidge J, Crane IJ. CX3CR1-deficiency is associated with increased severity of disease in experimental autoimmune uveitis. Immunology. 2009;128:25&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">19689733</ArticleId><ArticleId IdType="pmc">2747136</ArticleId></ArticleIdList></Reference><Reference><Citation>Beli E, Dominguez JM 2nd, Hu P, Thinschmidt JS, Caballero S, Li Calzi S, et al. CX3CR1 deficiency accelerates the development of retinopathy in a rodent model of type 1 diabetes. J Mol Med (Berl). 2016;94:1255&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pubmed">27344677</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawamura N, Katsuura G, Yamada-Goto N, Novianti E, Inui A, Asakawa A. Reduced brain fractalkine-CX3CR1 signaling is involved in the impaired cognition of streptozotocin-treated mice. IBRO Rep. 2020;9:233&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">32995659</ArticleId><ArticleId IdType="pmc">7509139</ArticleId></ArticleIdList></Reference><Reference><Citation>Mai W, Liu X, Wang J, Zheng J, Wang X, Zhou W. Protective effects of CX3CR1 on autoimmune inflammation in a chronic EAE model for MS through modulation of antigen-presenting cell-related molecular MHC-II and its regulators. Neurol Sci. 2019;40:779&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">30671738</ArticleId></ArticleIdList></Reference><Reference><Citation>Ridderstad Wollberg A, Ericsson-Dahlstrand A, Jureus A, Ekerot P, Simon S, Nilsson M, et al. Pharmacological inhibition of the chemokine receptor CX3CR1 attenuates disease in a chronic-relapsing rat model for multiple sclerosis. Proc Natl Acad Sci USA. 2014;111:5409&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">24706865</ArticleId><ArticleId IdType="pmc">3986185</ArticleId></ArticleIdList></Reference><Reference><Citation>Yadav AK, Kumar V, Jha V. Association of chemokine receptor CX3CR1 V249I and T280M polymorphisms with chronic kidney disease. Indian J Nephrol. 2016;26:275&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">27512300</ArticleId><ArticleId IdType="pmc">4964688</ArticleId></ArticleIdList></Reference><Reference><Citation>De Lema GP, Lucio-Caza&#xf1;a FJ, Molina ANA, Luckow B, Schmid H, de Wit C, et al. Retinoic acid treatment protects MRL/lpr lupus mice from the development of glomerular disease. Kidney Int. 2004;66:1018&#x2013;28.</Citation></Reference><Reference><Citation>Zhang H, Liao X, Sparks JB, Luo XM, Schloss PD. Dynamics of gut microbiota in autoimmune lupus. Appl Environ Microbiol. 2014;80:7551&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">25261516</ArticleId><ArticleId IdType="pmc">4249226</ArticleId></ArticleIdList></Reference><Reference><Citation>Mu Q, Zhang H, Liao X, Lin K, Liu H, Edwards MR, et al. Control of lupus nephritis by changes of gut microbiota. Microbiome. 2017;5:73.</Citation><ArticleIdList><ArticleId IdType="pubmed">28697806</ArticleId><ArticleId IdType="pmc">5505136</ArticleId></ArticleIdList></Reference><Reference><Citation>Mu Q, Edwards MR, Swartwout BK, Cabana Puig X, Mao J, Zhu J, et al. Gut microbiota and bacterial DNA suppress autoimmunity by stimulating regulatory B cells in a murine model of lupus. Front Immunol. 2020;11: 593353.</Citation><ArticleIdList><ArticleId IdType="pubmed">33240280</ArticleId><ArticleId IdType="pmc">7683516</ArticleId></ArticleIdList></Reference><Reference><Citation>Mu Q, Cabana-Puig X, Mao J, Swartwout B, Abdelhamid L, Cecere TE, et al. Pregnancy and lactation interfere with the response of autoimmunity to modulation of gut microbiota. Microbiome. 2019;7:105.</Citation><ArticleIdList><ArticleId IdType="pubmed">31311609</ArticleId><ArticleId IdType="pmc">6635999</ArticleId></ArticleIdList></Reference><Reference><Citation>Mu Q, Swartwout BK, Edwards M, Zhu J, Lee G, Eden K, et al. Regulation of neonatal IgA production by the maternal microbiota. Proc Natl Acad Sci. 2021. https://doi.org/10.1073/pnas.2015691118 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2015691118</ArticleId><ArticleId IdType="pubmed">34257153</ArticleId><ArticleId IdType="pmc">8307374</ArticleId></ArticleIdList></Reference><Reference><Citation>Bolger AM, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for illumina sequence data. Bioinformatics. 2014;30:2114&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">24695404</ArticleId><ArticleId IdType="pmc">4103590</ArticleId></ArticleIdList></Reference><Reference><Citation>Callahan BJ, McMurdie PJ, Rosen MJ, Han AW, Johnson AJ, Holmes SP. DADA2: high-resolution sample inference from Illumina amplicon data. Nat Methods. 2016;13:581&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pubmed">27214047</ArticleId><ArticleId IdType="pmc">4927377</ArticleId></ArticleIdList></Reference><Reference><Citation>McMurdie PJ, Holmes S. phyloseq: an R package for reproducible interactive analysis and graphics of microbiome census data. PLoS ONE. 2013;8: e61217.</Citation><ArticleIdList><ArticleId IdType="pubmed">23630581</ArticleId><ArticleId IdType="pmc">3632530</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin BD, Witten D, Willis AD. Modeling microbial abundances and dysbiosis with beta-binomial regression. Ann Appl Stat. 2020;14:94&#x2013;115.</Citation><ArticleIdList><ArticleId IdType="pubmed">32983313</ArticleId><ArticleId IdType="pmc">7514055</ArticleId></ArticleIdList></Reference><Reference><Citation>Oksanen J, Blanchet FG, Kindt R, Legendre P, Minchin PR, O&#x2019;Hara RB, Simpson GL, Solymos P, Stevens MHH, Wagner H. Vegan: community ecology package. R Package Version 2.2&#x2013;0; 2014. http://CRAN.Rproject.org/package=vegan .</Citation></Reference><Reference><Citation>Geng S, Zhang Y, Yi Z, Lu R, Li L. Resolving monocytes generated through TRAM deletion attenuate atherosclerosis. JCI Insight 2021; 6(20):e149651.</Citation></Reference><Reference><Citation>Geng S, Chen K, Yuan R, Peng L, Maitra U, Diao N, et al. The persistence of low-grade inflammatory monocytes contributes to aggravated atherosclerosis. Nat Commun. 2016;7:13436.</Citation><ArticleIdList><ArticleId IdType="pubmed">27824038</ArticleId><ArticleId IdType="pmc">5105176</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao X, Ren J, Wei CH, Ross AC, Cecere TE, Jortner BS, et al. Paradoxical effects of all-trans-retinoic acid on lupus-like disease in the MRL/lpr mouse model. PLoS&#xa0;One. 2015;10: e0118176.</Citation><ArticleIdList><ArticleId IdType="pubmed">25775135</ArticleId><ArticleId IdType="pmc">4361690</ArticleId></ArticleIdList></Reference><Reference><Citation>Reilly CM, Olgun S, Goodwin D, Gogal RM Jr, Santo A, Romesburg JW, et al. Interferon regulatory factor-1 gene deletion decreases glomerulonephritis in MRL/lpr mice. Eur J Immunol. 2006;36:1296&#x2013;308.</Citation><ArticleIdList><ArticleId IdType="pubmed">16541466</ArticleId></ArticleIdList></Reference><Reference><Citation>Cabana-Puig X, Bond JM, Wang Z, Dai R, Lu R, Lin A, et al. Phenotypic drift in lupus-prone MRL/lpr mice: potential roles of microRNAs and gut microbiota. Immunohorizons. 2022;6:36&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pubmed">35039434</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider KM, Bieghs V, Heymann F, Hu W, Dreymueller D, Liao L, et al. CX3CR1 is a gatekeeper for intestinal barrier integrity in mice: limiting steatohepatitis by maintaining intestinal homeostasis. Hepatology. 2015;62:1405&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pubmed">26178698</ArticleId></ArticleIdList></Reference><Reference><Citation>Medina-Contreras O, Geem D, Laur O, Williams IR, Lira SA, Nusrat A, et al. CX3CR1 regulates intestinal macrophage homeostasis, bacterial translocation, and colitogenic Th17 responses in mice. J Clin Invest. 2011;121:4787&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pubmed">22045567</ArticleId><ArticleId IdType="pmc">3226003</ArticleId></ArticleIdList></Reference><Reference><Citation>McGaha TL, Chen Y, Ravishankar B, van Rooijen N, Karlsson MC. Marginal zone macrophages suppress innate and adaptive immunity to apoptotic cells in the spleen. Blood. 2011;117:5403&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">21444914</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiao JH, Castellani LW, Fishbein MC, Lusis AJ. Immune-complex-mediated vasculitis increases coronary artery lipid accumulation in autoimmune-prone MRL mice. Arterioscler Thromb. 1993;13:932&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pubmed">8499414</ArticleId></ArticleIdList></Reference><Reference><Citation>Geng S, Zhang Y, Lee C, Li L. Novel reprogramming of neutrophils modulates inflammation resolution during atherosclerosis. Sci Adv. 2019;5: eaav2309.</Citation><ArticleIdList><ArticleId IdType="pubmed">30775441</ArticleId><ArticleId IdType="pmc">6365109</ArticleId></ArticleIdList></Reference><Reference><Citation>Pradhan K, Yi Z, Geng S, Li L. Development of exhausted memory monocytes and underlying mechanisms. Front Immunol. 2021;12: 778830.</Citation><ArticleIdList><ArticleId IdType="pubmed">34777396</ArticleId><ArticleId IdType="pmc">8583871</ArticleId></ArticleIdList></Reference><Reference><Citation>Aicher A, Hayden-Ledbetter M, Brady WA, Pezzutto A, Richter G, Magaletti D, et al. Characterization of human inducible costimulator ligand expression and function. J Immunol. 2000;164:4689&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pubmed">10779774</ArticleId></ArticleIdList></Reference><Reference><Citation>Wikenheiser DJ, Stumhofer JS. ICOS co-stimulation: friend or foe? Front Immunol. 2016;7:304.</Citation><ArticleIdList><ArticleId IdType="pubmed">27559335</ArticleId><ArticleId IdType="pmc">4979228</ArticleId></ArticleIdList></Reference><Reference><Citation>Li H, Adamopoulos IE, Moulton VR, Stillman IE, Herbert Z, Moon JJ, et al. Systemic lupus erythematosus favors the generation of IL-17 producing double negative T cells. Nat Commun. 2020;11:2859.</Citation><ArticleIdList><ArticleId IdType="pubmed">32503973</ArticleId><ArticleId IdType="pmc">7275084</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodriguez-Rodriguez N, Flores-Mendoza G, Apostolidis SA, Rosetti F, Tsokos GC, Crispin JC. TCR-&#x3b1;/&#x3b2; CD4(&#x2013;) CD8(&#x2013;) double negative T cells arise from CD8(+) T cells. J Leukoc Biol. 2020;108:851&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">32052478</ArticleId></ArticleIdList></Reference><Reference><Citation>Li H, Tsokos GC. Double-negative T cells in autoimmune diseases. Curr Opin Rheumatol. 2021;33:163&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">33394752</ArticleId><ArticleId IdType="pmc">8018563</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen PM, Tsokos GC. The role of CD8+ T-cell systemic lupus erythematosus pathogenesis: an update. Curr Opin Rheumatol. 2021;33:586&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">34183542</ArticleId><ArticleId IdType="pmc">8567317</ArticleId></ArticleIdList></Reference><Reference><Citation>Shivakumar S, Tsokos GC, Datta SK. T cell receptor alpha/beta expressing double-negative (CD4&#x2013;/CD8&#x2013;) and CD4+ T helper cells in humans augment the production of pathogenic anti-DNA autoantibodies associated with lupus nephritis. J Immunol. 1989;143:103&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">2525144</ArticleId></ArticleIdList></Reference><Reference><Citation>Crispin JC, Oukka M, Bayliss G, Cohen RA, Van Beek CA, Stillman IE, et al. Expanded double negative T cells in patients with systemic lupus erythematosus produce IL-17 and infiltrate the kidneys. J Immunol. 2008;181:8761&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">19050297</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizui M, Koga T, Lieberman LA, Beltran J, Yoshida N, Johnson MC, et al. IL-2 protects lupus-prone mice from multiple end-organ damage by limiting CD4-CD8- IL-17-producing T cells. J Immunol. 2014;193:2168&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pubmed">25063876</ArticleId></ArticleIdList></Reference><Reference><Citation>Cabeza-Cabrerizo M, Cardoso A, Minutti CM, Pereira da Costa M, Reis e Sousa C. Dendritic cells revisited. Annu Rev Immunol. 2021;39:131&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pubmed">33481643</ArticleId></ArticleIdList></Reference><Reference><Citation>Gottschalk C, Kurts C. The debate about dendritic cells and macrophages in the kidney. Front Immunol. 2015;6:435.</Citation><ArticleIdList><ArticleId IdType="pubmed">26388867</ArticleId><ArticleId IdType="pmc">4556034</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnold IC, Mathisen S, Schulthess J, Danne C, Hegazy AN, Powrie F. CD11c(+) monocyte/macrophages promote chronic Helicobacter hepaticus-induced intestinal inflammation through the production of IL-23. Mucosal Immunol. 2016;9:352&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">26242598</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu L, Kuroishi T, Tanaka Y, Furukawa M, Nochi T, Sugawara S. Differential expression of CD11c defines two types of tissue-resident macrophages with different origins in steady-state salivary glands. Sci Rep. 2022;12:931.</Citation><ArticleIdList><ArticleId IdType="pubmed">35042931</ArticleId><ArticleId IdType="pmc">8766464</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao Q, Wang Y, Wang XM, Lu J, Lee VW, Ye Q, et al. Renal F4/80+ CD11c+ mononuclear phagocytes display phenotypic and functional characteristics of macrophages in health and in adriamycin nephropathy. J Am Soc Nephrol. 2015;26:349&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">25012165</ArticleId></ArticleIdList></Reference><Reference><Citation>Borges da Silva H, Fonseca R, Pereira RM, Cassado Ados A, Alvarez JM, D&#x2019;Imperio Lima MR. Splenic macrophage subsets and their function during blood-borne infections. Front Immunol. 2015;6:480.</Citation><ArticleIdList><ArticleId IdType="pubmed">26441984</ArticleId><ArticleId IdType="pmc">4585205</ArticleId></ArticleIdList></Reference><Reference><Citation>Helmke A, Nordlohne J, Balzer MS, Dong L, Rong S, Hiss M, et al. CX3CL1-CX3CR1 interaction mediates macrophage-mesothelial cross talk and promotes peritoneal fibrosis. Kidney Int. 2019;95:1405&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pubmed">30948201</ArticleId></ArticleIdList></Reference><Reference><Citation>Kassianos AJ, Wang X, Sampangi S, Afrin S, Wilkinson R, Healy H. Fractalkine-CX3CR1-dependent recruitment and retention of human CD1c+ myeloid dendritic cells by in vitro-activated proximal tubular epithelial cells. Kidney Int. 2015;87:1153&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">25587706</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>